FRTX-10
/ Fresh Tracks Therap, Carna Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 14, 2022
FRESH TRACKS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
(Market Screener)
- "In February 2022, we acquired exclusive, worldwide rights to research, develop, and commercialize a portfolio of novel, preclinical-stage oral Stimulator of Interferon Genes ('STING') inhibitors. STING is a well-known mediator of innate immune responses. Excessive signaling through STING is linked to numerous high unmet-need diseases, ranging from autoimmune disorders, such as systemic lupus erythematosus, to interferonopathies, which are a set of rare genetic conditions characterized by interferon overproduction and could have orphan drug potential."
Preclinical • Interferonopathies • STING-Associated Vasculopathy with Onset in Infancy
August 11, 2022
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
- "Brickell Biotech...Research and Development Highlights...BBI-10: a covalent Stimulator of Interferon Genes (STING) inhibitor for the potential treatment of autoimmune, inflammatory, and rare genetic diseases Preclinical development activities for BBI-10, the Company’s lead STING inhibitor candidate, are underway."
Preclinical • Interferonopathies • STING-Associated Vasculopathy with Onset in Infancy
1 to 2
Of
2
Go to page
1